Morepen Laboratories Limited (MOREPENLAB) AI Stock Analysis

• Market Cap: ₹20.86B
• Dividend Yield: 0.49%
• Average Volume (3M): 88.30K
• Price to Earnings (P/E): 20.5
• Beta (1Y): 1.86
• Revenue Growth: -0.29%
• EPS Growth: -29.04%
• Country: IN
• Employees: 2,152
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.50
• Shares Outstanding: 547,953,700
• 10 Day Avg. Volume: 126,704
• 30 Day Avg. Volume: 88,304
• PEG Ratio: 1.32
• Price to Book (P/B): 2.29
• Price to Sales (P/S): 1.45
• P/FCF Ratio: -28.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹39.00 ▼(-7.12% Downside)
• Action: Reiterated Date: 11/25/25
• Date: Action: Reiterated 11/25/25

The overall stock score for Morepen Laboratories Limited is primarily influenced by its strong financial performance, despite challenges in profitability margins and cash flow management. Technical analysis indicates bearish momentum, which negatively impacts the score. The valuation suggests moderate pricing, but the low dividend yield limits income potential. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Consistent Revenue Growth

Revenue grew 7.5% year-over-year to 2025, reflecting steady demand across APIs and formulations. Durable top-line expansion supports scale benefits in manufacturing, strengthens bargaining power with customers, and underpins longer-term reinvestment capacity and capacity utilization.

Strong Balance Sheet / Low Leverage

Very low leverage (D/E 0.09) and a 65% equity ratio give structural financial resilience. This reduces refinancing risk, enables selective capital spending or contract wins, and provides buffer during pharma cycle volatility, supporting stable operations and strategic flexibility.

Healthy Gross and Operating Margins

Robust gross (34.4%) and EBIT (17.3%) margins indicate efficient manufacturing and favorable product mix in APIs and formulations. These structural margins support cash generation potential, pricing competitiveness, and long-term ability to fund R&D or contract manufacturing investments.

Negative Factors

Declining Net Profit Margin

Net margin contraction to 6.5% signals pressure beneath the operating line, reducing retained earnings available for reinvestment. If persistent, it may reflect rising SG&A, input cost pressure, or lower-priced contract wins, impairing sustainable profitability and ROE expansion.

Negative Free Cash Flow

Negative free cash flow in 2025 points to capex or working capital absorption outpacing cash generation. Structural FCF deficits limit self-funded growth, increase reliance on external financing, and constrain ability to build reserves or increase dividends over the medium term.

Earnings Decline / EPS Volatility

A ~24% decline in EPS indicates earnings volatility or one-off impacts that reduce shareholder returns. Persistent EPS contraction undermines investment capacity and may signal competitive or cost challenges in core API/formulation segments, raising execution risk for strategic initiatives.

Morepen Laboratories Limited Business Overview & Revenue Model

Company Description

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.

How the Company Makes Money

Morepen Laboratories primarily makes money through (1) sales of active pharmaceutical ingredients (APIs) and (2) sales of finished dosage formulations. API revenue is generated by manufacturing bulk drug intermediates/finished APIs and selling them to other pharmaceutical companies that use these inputs to produce their own medicines; earnings depend on volumes sold, product mix, pricing, and export vs. domestic demand. Formulations revenue comes from selling finished medicines (such as tablets/capsules/other dosage forms) through branded marketing channels and/or supplying formulations under contract manufacturing arrangements for other companies; earnings in this segment are driven by portfolio breadth, distribution reach, tender/contract wins, and regulatory approvals for marketed/exported products. If present, additional income can come from exports (including currency effects), long-term supply arrangements with pharmaceutical customers, and manufacturing scale/efficiency improvements; specific named partnerships or customer details are null.

Morepen Laboratories Limited Financial Statement Overview

Summary

Morepen Laboratories Limited exhibits strong revenue growth and a solid financial structure, with a low debt profile and effective equity utilization. However, profitability margins have shown a decline, and cash flow management poses challenges, with negative free cash flow highlighting liquidity risks. Continued focus on operational efficiency and cash flow improvement is essential for sustaining its financial health.

Income Statement

The company has shown a consistent revenue growth over the years with a 7.5% increase from 2024 to 2025. The gross profit margin remains healthy at 34.4% for 2025, although the net profit margin has decreased to 6.5% compared to the previous year. The EBIT and EBITDA margins indicate a robust operational efficiency at 17.3% and 10.5% respectively for 2025. However, the drop in profitability margins signifies potential operational challenges.

Balance Sheet

The balance sheet reflects strong financial stability with a debt-to-equity ratio of 0.09 in 2025, indicating low leverage. Return on equity (ROE) stands at 10.2%, suggesting efficient utilization of equity. The equity ratio of 65.0% points to a sound capital structure. Overall, the company maintains a low-risk financial position with ample equity backing.

Cash Flow

The company faces challenges with cash flow management, as evidenced by a negative free cash flow in 2025, despite experiencing a significant increase in operating cash flow. The free cash flow to net income ratio is negative, indicating potential liquidity concerns. However, the operating cash flow to net income ratio of 0.27 suggests some degree of cash generation capability.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	17.60B	18.30B	17.02B	14.18B	15.42B	11.75B
Gross Profit	6.15B	6.30B	6.18B	2.19B	4.81B	3.89B
EBITDA	1.69B	1.92B	1.73B	856.66M	1.57B	1.30B
Net Income	986.27M	1.18B	961.60M	386.75M	1.02B	970.86M
Balance Sheet
Total Assets	17.36B	17.78B	12.93B	11.10B	10.70B	8.58B
Cash, Cash Equivalents and Short-Term Investments	932.86M	1.27B	169.45M	216.66M	158.03M	413.87M
Total Debt	1.58B	1.05B	289.99M	251.64M	1.33B	1.37B
Total Liabilities	5.39B	5.91B	4.46B	3.58B	4.92B	4.34B
Stockholders Equity	11.96B	11.56B	8.47B	7.53B	5.79B	4.25B
Cash Flow
Free Cash Flow	-247.12M	-919.76M	-79.61M	-1.37B	-1.25B	104.27M
Operating Cash Flow	158.61M	320.57M	733.75M	-911.71M	-577.58M	508.26M
Investing Cash Flow	-516.43M	-3.22B	-833.00M	-465.09M	-316.79M	-703.51M
Financing Cash Flow	444.06M	3.00B	52.05M	1.44B	663.34M	472.73M

Morepen Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 41.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MOREPENLAB, the sentiment is Negative. The current price of 41.99 is above the 20-day moving average (MA) of 40.82, above the 50-day MA of 39.10, and below the 200-day MA of 48.72, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 43.23 is Neutral, neither overbought nor oversold. The STOCH value of 18.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MOREPENLAB.

Morepen Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPGLIFE	76 Outperform	₹31.11B	43.39	―	0.85%	―	―
UNICHEMLAB	61 Neutral	₹21.71B	2.94	―	―	25.42%	―
MOREPENLAB	57 Neutral	₹20.86B	20.54	―	0.49%	-0.29%	-29.04%
GUFICBIO	57 Neutral	₹29.49B	67.80	―	0.03%	7.78%	-34.68%
MEDIASSIST	54 Neutral	₹23.82B	205.09	―	0.92%	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PANACEABIO	51 Neutral	₹19.44B	144.78	―	―	9.78%	50.78%

Morepen Laboratories Limited Corporate Events

Morepen Labs Wins ₹825 Crore Global CDMO Contract From Pharma Major

Morepen Laboratories has secured an international commercial supply contract worth approximately ₹825 crore (about USD 91 million) from a leading global pharmaceutical company under a CDMO arrangement for development and/or manufacturing services. Supplies under the contract are expected to begin within four to five months and execution is slated over a 12–15 month period through the first quarter of the next fiscal year, marking a significant expansion of Morepen’s presence in the high-growth global CDMO segment and strengthening its position as a partner to multinational drug makers.

The contract, awarded by an unrelated overseas entity and confirmed as not a related-party transaction, underscores rising global demand for outsourced development and manufacturing from Indian pharma players. For Morepen, the sizeable order enhances revenue visibility, supports better utilization of manufacturing capacity and could improve its competitive standing in international markets, while signaling confidence from a major global client in its technical and regulatory capabilities.

Morepen Labs Wins ₹825 Crore Global CDMO Mandate to Scale Manufacturing Platform

Morepen Laboratories has secured a multi-year CDMO mandate worth about ₹825 crore from a leading global pharmaceutical major, in what it describes as one of the largest single CDMO contracts in its history. Supplies are slated to begin within four to five months and continue through the first quarter of the next financial year, subject to standard operational and regulatory clearances.

The deal expands Morepen’s presence in the high-growth CDMO segment, leveraging its long-standing API capabilities and globally compliant manufacturing infrastructure. Management views CDMO as a natural extension of its core strengths, indicating that the company is evaluating capacity and technology investments to support complex, long-duration global programs and enhance long-term scale and stability for stakeholders.

Morepen Labs Reports Minimal Activity in SEBI Special Window for Physical Share Transfers

Morepen Laboratories has reported to the stock exchanges on the status of shareholder requests for re-lodgement of physical share transfer requests under a special six-month window mandated by the Securities and Exchange Board of India (SEBI). For the period from 1 January 2026 to 6 January 2026, the company’s registrar and share transfer agent, MAS Services Limited, confirmed that one request for re-lodgement of physical share transfer was received and processed, with the request being rejected and no approvals granted, indicating minimal activity and a limited operational impact from the SEBI special window during this initial period.